A phase 1, randomized, double-blind, placebo-controlled, ascending dose study evaluating the safety, tolerability and pharmacokinetics of JTK-652 administered for two weeks in healthy male subjects

Completed

Conditions: Hepatitis
10019654
10047438

Registration Number: NL-OMON31189

Lead Sponsor: Japan Tobacco, Inc.

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 18

Inclusion Criteria

Man
Age : 18-55 yr
BMI : 19-28 kg/m2, inclusive

Exclusion Criteria

Current abuse of alcohol or/and drugs
Clinical significant indications in man's medical history

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety : AE's, clinical laboratory parameters, vital signs, ECG and physical<br /><br>examination<br /><br>Pharmacokinetics : plasma JTK-652 concentrations, pharmacokinetics parameters</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Nvt</p><br>

Related Trials

A phase 1, randomized, double-blind, placebo-controlled, multiple dose platform study investigating the immunopharmacology of EDP1815 and EDP2939

Completed

Evelo Biosciences

Updated 4/9/2024

A phase 1, randomized, double-blind, placebo-controlled, single-dose escalation, multiple-dose escalation, and food effect study of RPT193 in healthy subjects and patients with moderate to severe atopic dermatitis

Completed

RAPT Therapeutics, Inc.

Updated 4/15/2024

A phase 1, randomized, double-blind, placebo-controlled study evaluating the pharmacokinetics of capsule and tablet formulations of VX-150, including the effects of food and milk, the relative bioavailability of the tablet formulation, and the drug-drug interaction between VX-150 and Midazolam, in healthy adults

Completed

Vertex Pharmaceuticals Incorporated

Updated 2/28/2024

A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study evaluating safety and pharmacokinetics of VX-150 including an assessment of the effect of food on the pharmacokinetics of VX-150 in healthy adult subjects.

Completed

Vertex Pharmaceuticals Incorporated

Updated 2/28/2024

A phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of multiple ascending doses of ESB1609 in healthy volunteers.

Completed

ESCAPE Bio, Inc.

Updated 4/15/2024

A phase 1, randomized, double-blind, placebo-controlled, sequential-panel, ascending single-dose study to evaluate the safety, tolerability, and pharmacokinetics of intravenous CMX-020 in healthy male and female subjects

CompletedPhase 1

Cytometix Inc

Updated 11/12/2018

A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of PRAX-628 in healthy participants

Phase 1

Praxis Precision Medicines

Updated 2/27/2023

A phase 1, randomized, double-blind, placebo-controlled, escalating single- and multiple-dose study to evaluate the safety, tolerability and pharmacokinetics of EYP001a in healthy male subjects.

Completed

ENYO Pharma SAS

Updated 2/28/2024

A phase 1, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the safety, tolerability, and pharmacokinetics of LMT503 in healthy subjects.

mito Therapeutics Inc.

Updated 4/9/2024

A phase 1, randomized, double-blind, placebo-controlled, single-site study to assess the safety, tolerability, pharmacokinetics and food effect of MIN-102 following oral administration of single and multiple ascending doses in healthy male volunteers

Completed

Minoryx Therapeutics S.L.

Updated 4/23/2024

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy

A phase 1, randomized, double-blind, placebo-controlled, ascending dose study evaluating the safety, tolerability and pharmacokinetics of JTK-652 administered for two weeks in healthy male subjects

Recruitment & Eligibility

Study & Design

Related Research Topics

Related Trials

A phase 1, randomized, double-blind, placebo-controlled, multiple dose platform study investigating the immunopharmacology of EDP1815 and EDP2939

A phase 1, randomized, double-blind, placebo-controlled, single-dose escalation, multiple-dose escalation, and food effect study of RPT193 in healthy subjects and patients with moderate to severe atopic dermatitis

A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study evaluating safety and pharmacokinetics of VX-150 including an assessment of the effect of food on the pharmacokinetics of VX-150 in healthy adult subjects.

A phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of multiple ascending doses of ESB1609 in healthy volunteers.

A phase 1, randomized, double-blind, placebo-controlled, sequential-panel, ascending single-dose study to evaluate the safety, tolerability, and pharmacokinetics of intravenous CMX-020 in healthy male and female subjects

A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of PRAX-628 in healthy participants

A phase 1, randomized, double-blind, placebo-controlled, escalating single- and multiple-dose study to evaluate the safety, tolerability and pharmacokinetics of EYP001a in healthy male subjects.

A phase 1, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the safety, tolerability, and pharmacokinetics of LMT503 in healthy subjects.

A phase 1, randomized, double-blind, placebo-controlled, single-site study to assess the safety, tolerability, pharmacokinetics and food effect of MIN-102 following oral administration of single and multiple ascending doses in healthy male volunteers

Clinical Trial Alerts

Clinical Trial Alerts